Work Schedule / Location

A mix of remote and in-person.


Michael Dorsch is the Lynda S. Welage Collegiate Professor of Pharmacy who studies digital health. His current work focuses on patient and provider-centered clinical decision support. Dr. Dorsch received his PharmD from Ohio Northern University. He completed a PGY1 pharmacy practice residency at Riverside Methodist Hospital in Columbus, Ohio, and a PGY2 cardiology specialty residency at the University of North Carolina Hospitals in Chapel Hill. He earned an MS in clinical research design and statistical analysis from the University of Michigan with an institutional K30 award from the Michigan Institute for Clinical & Health Research. Dr. Dorsch is a Board Certified Cardiology Pharmacist and named Fellow of the American College of Clinical Pharmacy, American Heart Association, and American College of Cardiology.

Research Interests

  • Health Information Technology

    • mHealth
    • Clinical decision support
    • Computable biomedical knowledge
  • Cardiovascular Disease Outcomes Research

    • Quality improvement
    • Health services research
  • Educational Research

    • Cirricular quality improvement
    • Team-based learning
  • If you would like to fund my research, click on the button below and add my full name where it says "Write in".


    UM Giving



Selected Publications

  • Dorsch MP, Sifuentes A, Cordwin DJ, Kuo R, Rowell BE, Arzac JJ, DeBacker K, Guidi JL, Hummel SL, Koelling TM. A Computable Algorithm for Medication Optimization in Heart Failure with Reduced Ejection Fraction. JACC Advances. 2023;2(3):100289.

  • Dorsch MP, Chen CS, Allen AL, Sales AE, Seagull FJ, Spoutz P, Sussman JB, Barnes GD. Nationwide Implementation of a Population Management Dashboard for Monitoring Direct Oral Anticoagulants: Insights From the Veterans Affairs Health System. Circ Cardiovasc Qual Outcomes. 2023 Feb;16(2):e009256.

  • Vordenberg SE, Maitah Y, Khan Z, DeBacker K, Dorsch MP. Consumer perceptions of the OTC Coach: A clinical decision support system aimed at improving the safe use of over-the-counter medications. J Am Pharm Assoc (2003). 2023 Jan-Feb;63(1):135-143.

  • Eze CE, West BT, Dorsch MP, Coe AB, Lester CA, Buis LR, Farris K. Predictors of Smartphone and Tablet Use Among Patients With Hypertension: Secondary Analysis of Health Information National Trends Survey Data. J Med Internet Res. 2022 Jan 24;24(1):e33188.

  • Dorsch MP, Farris KB, Rowell BE, Hummel SL, Koelling TM. The Effects of the ManageHF4Life Mobile App on Patients With Chronic Heart Failure: Randomized Controlled Trial. JMIR Mhealth Uhealth. 2021 Dec 7;9(12):e26185.

  • Campos-Staffico AM, Cordwin D, Murthy VL, Dorsch MP, Luzum JA. Comparative performance of the two pooled cohort equations for predicting atherosclerotic cardiovascular disease. Atherosclerosis. 2021; 334:23-39.

  • Campos-Staffico AM, Cordwin D, Ding Y, Lester CA, Brook RD, Luzum JA, Dorsch MP. Fewer patients receive recommendations for pharmacotherapy in primary prevention using the 2018 atherosclerotic cardiovascular disease risk estimator. Prev Med. 2021 Jul;148:106555.

  • Krishnaswami A, Beavers C, Dorsch MP, Dodson JA, Masterson Creber R, Kitsiou S, Goyal P, Maurer MS, Wenger NK, Croy DS, Alexander KP, Batsis JA, Turakhia MP, Forman DE, Bernacki GM, Kirkpatrick JN, Orr NM, Peterson ED, Rich MW, Freeman AM, Bhavnani SP. Gerotechnology for Older Adults With Cardiovascular Diseases: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Dec 1;76(22):2650-2670.

  • Lester CA, Coe AB, Dorsch MP, Farris KB, Flynn AJ. A learning pharmacy practice enabled by the pharmacists' patient care process [published online ahead of print, 2020 Jun 30]. J Am Pharm Assoc (2003). 2020;S1544-3191(20)30249-1.

  • Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. January 2020. doi:10.1007/s11239-020-02037-3

  • Dorsch MP, Lester CA, Ding Y, Joseph M, Brook RD. Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System. J Am Heart Assoc. 2019;8(22):e014709.

  • Adie S, Bitar A, Hanigan S, Pogue KT, Koelling TM, Dorsch MP. Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure. J Card Fail. 2019 May;25(5):412-413.

  • Rollins A, Hanigan S, Pogue K, Renner E, Barnes G, Dorsch M. Identifying Clinical Predictors of Switching From Direct Oral Anticoagulants to Warfarin. Clinical Medicine Insights: Therapeutics. 2019;11:1179559X19831287.

  • Bleske BE, Remington TL, Wells TD, Klein KC, Dorsch MP. A Randomized Crossover Comparison between Team-Based Learning and Lecture Format on Long-Term Learning Outcomes. Pharmacy 2018 Aug 4;6(3). pii: E81.

  • Dorsch MP, Chong YP, McCormick MP, Grossi J, Farris KB, Koelling TM, Bleske BE. Survey of Computer, Smart Devices, and Internet use in Heart Failure Patients. International Cardiovascular Forum Journal. 2016;6:84-85.

  • Dorsch MP, Farris KB, Bleske BE, Koelling TM. A web application for self-monitoring improves symptoms in chronic systolic heart failure. Telemed J E Health. 2015;21(4):267-70.

  • Bleske BE, Dillman NO, Cornelius D, Ward JK, Burson SC, Diez HL, Pickworth KK, Bennett MS, Nicklas JM, Dorsch MP. Heart failure assessment at the community pharmacy level: a feasibility pilot study. J Am Pharm Assoc. 2014 Nov-Dec;54(6):634-41.

  • Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared to hydrochlorothiazide: A retrospective cohort analysis. Hypertension 2011 Apr;57(4):689-94.


    Full List of Publications